Ribavirin dosing in chronic hepatitis C: Application of population pharmacokinetic‐pharmacodynamic models

Background Combination therapy of ribavirin with interferon alfa‐2b and pegylated interferon alfa‐2b is currently approved for the treatment of chronic hepatitis C. Approved ribavirin dosages vary from a fixed dosage of 800 mg/d to as much as 1200 mg/d on the basis of body weight. Objective Our obje...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical pharmacology and therapeutics 2002-10, Vol.72 (4), p.349-361
Hauptverfasser:	Jen, Juif, Laughlin, Mark, Chung, Carol, Heft, Samuel, Affrime, Melton B., Gupta, Samir K., Glue, Paul, Hajian, Gerald
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antibiotics. Antiinfectious agents. Antiparasitic agents Antiviral agents Biological and medical sciences Confidence Intervals Dose-Response Relationship, Drug Female Hepatitis C, Chronic - drug therapy Hepatitis C, Chronic - metabolism Humans Logistic Models Male Medical sciences Models, Biological Pharmacology. Drug treatments Ribavirin - administration & dosage Ribavirin - adverse effects Ribavirin - pharmacokinetics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!